Velimogene aliplasmid lipid complex: Antitumor gene therapy

Drugs of the Future

Volumn 32, Issue 10, 2007, Pages 874-878

  Kudchadkar, Ragini ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOVECTIN 7; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID LIPID COMPLEX;

ANEMIA; ARTICLE; BLEEDING; CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOTENSION; INJECTION SITE REACTION; MELANOMA; METASTASIS; NATURAL KILLER CELL; NAUSEA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAIN; PNEUMOTHORAX; TUMOR BIOPSY;

EID: 36749097849     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.10.1135520     Document Type: Article

References (27)

1. Friedmann, T., Roblin, R. Gene therapy for human genetic disease? Science 1972, 175(25): 949-55.
2. Verma, I.M., Somia, N. Gene therapy: Promises, problems and prospects. Nature 1997, 389(6648): 239-42.
3. Lewis, K.D., Humes, T.N., Gonzalez, R. Current status and future prospects of gene therapy: Focus on Allovectin-7® in the treatment of melanoma. Am J Cancer 2005, 4(3): 137-44.
4. Purcell, D.F., Broscius, C.M., Vanin, E.F., Buckler, C.E., Nienhuis, A.W., Martin, M.A. An array of murine leukemia virus-related elements is transmitted and expressed in primate recipient of retroviral gene transfer. J Virol 1996, 70(2): 887-97.
5. Li, Z., Dullmann, J., Schiedlmeier, B. et al. Murine leukemia induced by retroviral gene marking. Science 2002, 296(5567): 497.
6. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644): 415-9.
7. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E., Wilson, J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1996, 91(10): 4407-11.
8. Niidome, T., Huang, L. Gene therapy progress and prospects: Non-viral vectors. Gene Ther 2002, 9(24): 1647-52.
9. Morsy, M.A., Mitani, K., Clemens, P., Caskey, C.T. Progress toward human gene therapy. JAMA - J Am Med Assoc 1993, 270(19): 2238-45.
10. Galanis, E. Technology evaluation: Altovectin-7®, Vical. Curr Opin MoI Ther 2002, 4(1): 80-7.
11. Bergen, M., Chen, R., Gonzalez, R. Efficacy and safety of HLA-B7/B2-microglobulin plasmid DNA/lipid complex (Allovectin-7®) in patients with metastatic melanoma. Expert Opin Biol Ther 2003, 3(2): 377-84.
12. Esteban, F., Cancha, A., Delgado, M., Perez-Ayala, M., Ruiz-Cabello, F., Garrido, F. Lack of MHC class I antigens and tumor aggressiveness of squamous cell carcinoma of the larynx. Br J Cancer 1990, 62(6): 1047-51.
13. Mattijssen, V., De Mulder, P.H., Schalwijk, L., Manni, J.J., Van't Hof-Grootenboer, B., Ruiter, D.J. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991, 6: 95-100.
14. D'Urso, C.M., Wang, Z.G., Cao, Y., Tatake, R., Zeff, R.A., Ferrone, S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2M gene expression. J Clin Invest 1991, 87(1): 284-92.
15. Plautz, G.E., Yang, Z.Y., Wu, B.Y., Gao, X., Huang, L., Nabel, G.J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993, 90(10): 4645-9.
16. Nabel, G.J., Nabel, E.G., Yang, Z.Y. et al. Direct gene transfer with DNA-lipsome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993, 90(23): 11307-11.
17. Horn, N.A., Meek, J.A., Budahazi, G., Marquet, M. Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials. Hum Gene Ther 1995, 6(5): 565-73.
18. Parker, S.E., Ducharme, S., Norman, J., Wheeler, C.J. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997, 8(4): 393-401.
19. Lew, D., Parker, S.E., Latimer, T. et al. Cancer gene therapy using plasmid DNA: Pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995, 6(5): 553-64.
20. Rini, B.I., Selk, L.M., Vogelzang, N.J. Phase I study of direct intralesional gene transfer of HLA-b7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999, 5(10): 2766-72.
21. Stopeck, A.T., Hersh, E.M., Akporiaye, E.T. et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997, 15(1): 341-9.
22. Gleich, L.L., Guckman, J.L., Nemunaitis, J. et al. Clinical experience with HLA-B7 plasmid DNA/lipid complexes in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001, 127(7): 775-9.
23. Nabel, G.J., Gordon, D., Bishop, D.K. et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996, 93(26): 15388-93.
24. Stopeck, A.T., Jones, A., Hersh, E.M. et al. Phase II study of direct intralesional gene transfer of Allovectin-7®, and HLA-B7, in patients with metastatic melanoma. Clin Cancer Res 2001, 7(8): 2285-91.
25. Richards, J.M., Bedikian, A., Gonzalez, R. et al. High-dose Allovectin-7® in patients with advanced metastatic melanoma: Final phase 2 data and design of phase 3 registration trial. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 7543.
26. Gonzalez, R., Hutchins, L., Nemunaitis, J., Atkins, M., Schwarzenberger, P.O. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006, 16(6): 521-6.
27. A phase 3 pivotal trial comparing Allovectin-7® alone vs chemotherapy alone in patients with stage 3 or 4 melanoma (NCT00395070). ClinicalTrials.gov Web site, September 12, 2007.